Sugi Predict

Sugi Predict / Compounds / SCHEMBL505907

SCHEMBL505907

SCHEMBL505907

CC1(C)OB(c2ccc(=O)n(C3CCOC3)c2)OC1(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 1/20 0.35
▸ ATR Q13535 1/20 0.34
▸ LPL P06858 7/20 0.34
▸ LIPG Q9Y5X9 7/20 0.34
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA3 P07451 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA5A P35218 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ CA5B Q9Y2D0 1/20 0.33
▸ KRAS P01116 2/20 0.33
▸ SOS1 Q07889 2/20 0.33
▸ ADORA2A P29274 1/20 0.32
▸ ADORA2B P29275 1/20 0.32
▸ ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14730026 0.92 LPL (0.36) LPLLIPGCA1CA2CA9
SCHEMBL21722599 0.89 LPL (0.37) LPLLIPGCA1CA2CA9
SCHEMBL16465375 0.86 LPL (0.39) LPLLIPGCA1CA2CA9
SCHEMBL22655333 0.84 LPL (0.37) LPLLIPGCA1CA2CA9
SCHEMBL505933 0.84 LPL (0.37) LPLLIPGCA1CA2CA9
SCHEMBL22553373 0.79 LPL (0.36) LPLLIPGCA1CA2CA9
SCHEMBL22553466 0.78 LPL (0.35) LPLLIPGCA1CA2CA9
SCHEMBL20099665 0.77 LPL (0.33) LPLLIPG
SCHEMBL22655365 0.76 ACVRL1 (0.41) LPLLIPGCA1CA2CA9
SCHEMBL18152064 0.73 HCAR1 (0.33) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11629147-B2 Triazolo-pyrimidine compounds and uses thereof DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-04-18 — — US disclosed
CN-112279852-B Triazolo-pyrimidine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2023-01-17 — — CN disclosed
CN-111635408-B Triazolo-pyrimidine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2022-07-22 — — CN disclosed
EP-3849983-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) 2021-07-21 — — EP disclosed
CN-112279852-A Triazolo-pyrimidine compounds and uses thereof 迪哲(江苏)医药股份有限公司 2021-01-29 — — CN disclosed
US-20210009600-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-01-14 — — US disclosed
US-20210009600-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-01-14 — — US disclosed
US-10858365-B2 Triazolo-pyrimidine compounds and uses thereof DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-12-08 — — US disclosed
US-10858365-B2 Triazolo-pyrimidine compounds and uses thereof DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-12-08 — — US disclosed
US-20200331918-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-10-22 — — US disclosed
US-20200331918-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-10-22 — — US disclosed
CN-111635408-A Triazolo-pyrimidine compounds and uses thereof 迪哲（江苏）医药有限公司 2020-09-08 — — CN disclosed
CN-111601809-A Triazolo-pyrimidine compounds and uses thereof 迪哲（江苏）医药有限公司 2020-08-28 — — CN disclosed
WO-2020052631-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-03-19 — — WO disclosed
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 — — US disclosed
EP-2569313-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 — — EP disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 — — US disclosed
WO-2011143426-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009600-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF ADORA2A, ADORA3, ADORA2B MAP4K1 1776/4885ATR 1298/4885LPL 2247/4885
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 MAP4K1 28/4885ATR 1/4885LPL 4640/4885
US-11629147-B2 Triazolo-pyrimidine compounds and uses thereof ADORA2A, ADORA3, ADORA2B MAP4K1 1776/4885ATR 1298/4885LPL 2247/4885
US-10858365-B2 Triazolo-pyrimidine compounds and uses thereof ADORA2A, ADORA3, ADORA2B MAP4K1 1776/4885ATR 1298/4885LPL 2247/4885
US-20200331918-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF ADORA2A, ADORA3, ADORA2B MAP4K1 1776/4885ATR 1298/4885LPL 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.